AwardNo Set aside used$340.9M

RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)view on SAM.gov

HEALTH AND HUMAN SERVICES, DEPARTMENT OF › BARDA - ASPR / DAAPPO / BARDA DCMA

Posted Sep 30, 2026

Washington, DC

NAICS 541714 – Research and Development in Biotechnology (except Nanobiotechnology)

Sol # 75A50126C00010

Awardee: KALEO, INC.

AI Summary

• BARDA requires development and procurement of 2-PAM autoinjectors to treat organophosphate poisoning.
• This acquisition is unrestricted, with no specified set-aside program.
• Development includes late-stage clinical and regulatory approval for adult and pediatric populations.
• Procurement is for the SNS/CHEMPACK Program.

Description

This acquisition will allow BARDA to invest Project Bioshield funds for late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.

Award Details

Contract #75A50126C00010

Award DateSep 28, 2026

Amount$340.9M

AwardeeKALEO, INC.

Awardee LocationGlen Allen, VA, 23060

Classification

NAICS541714

PSC CodeAB12

Place of Performance

CityWashington

StateDC

ZIP20024

CountryUNITED STATES

Contracting Office

OfficeBARDA - ASPR / DAAPPO / BARDA DCMA

CityWASHINGTON

StateDC

ZIP20515

Contacts

Erin Greninger, Contracting Officer

erin.greninger@hhs.gov

Greg Smith(secondary)

greg.smith1@hhs.gov